APT Medical (688617) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached RMB 564.28 million, up 23.93% year-over-year.

• Net profit attributable to shareholders was RMB 183.15 million, a 30.69% increase year-over-year.

• Operating cash flow rose 45.45% year-over-year to RMB 166.66 million.

Financial highlights

• Basic EPS was RMB 1.89, up 30.34% year-over-year; diluted EPS was RMB 1.88, up 30.56%.

• Gross margin improved as operating profit rose to RMB 215.67 million from RMB 157.98 million year-over-year.

• R&D investment totaled RMB 73.97 million, accounting for 13.11% of revenue.

• Total assets at quarter-end were RMB 3.14 billion, up 5.50% from year-end 2024.

• Shareholders’ equity increased 7.34% to RMB 2.70 billion.

Outlook and guidance

• Profit growth attributed to expanded sales scale, enhanced product profitability, and cost control.